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ABSTRACT 
A five-year project, Access to Care was developed and implemented by the Sickle Cell Foundation of Georgia (SCFG) leveraging                   
community resources and partnerships to increase access and improve the quality of healthcare and healthcare coordination in an                  
adult sickle cell disease (SCD) population in underserved and rural areas of Georgia. The project is comprised of three phases:                    
(Phase 1) the Community Health Worker Program - to improve the health outcomes of individuals living with SCD through                   
healthcare coordination; (Phase 2) the CME-accredited Provider Training Program - to increase the knowledge of non-specialty                
providers in Georgia to increase provider capacity and confidence to provide care and treatment for individuals with sickle cell                   
disease; and (3) Sickle Cell Clinic Days – specialty care provided by a hematologist in minimally resourced and underserved                   
areas including Augusta, Columbus, Macon and Savannah and counties. Eight hundred and sixty-nine (869) individuals in 75                 
Georgia counties have received care coordination services with 113 placed in medical homes. Three hundred and sixty-eight (368)                  
health care providers have participated in six face-to-face trainings and 30 have participated in two webinars. Partnerships include                  
local sickle cell associations and support groups; local health departments; hospitals/Emergency Departments; local medical              
societies; local academic institutions; stakeholders; Georgia Department of Public Health; Global Blood Therapeutics; and              
Morehouse School of Medicine. With 8,427 residents living with SCD, Georgia has the nation’s fourth largest SCD population in                   
the nation with the second highest SCD incidence among black and/or African American births in the nation. Evaluation measures                   
include process and output data monitoring, collection of observational data, i.e., participation and appointment tracking, and case                 
management recording utilizing case management software; pre-and post-questionnaires to measure changes in knowledge,             
attitudes, skills covered in workshops and seminars. 
 






The quality of life of individuals living with a chronic          
condition is, in part, impacted by their access to appropriate          
health care. Access to care is also one component of          
preventing or delaying complications, improving function,      
delaying pain, and managing disease     
(https://www.healthypeople.gov/2020/). The Sickle Cell    
Foundation of Georgia’s (SCFG) Access to Care Project is         
designed to increase access, quality, and the level of         
healthcare coordination for individuals living with sickle       
cell disease (SCD) in the state of Georgia; diversify and          
enrich Georgia’s talent pool of primary care and family         
physicians with continuing medical education     
(CME)-accredited training on the treatment of SCD; and        
increase access to specialty (clinical) services for adult        
out-of-care individuals living with SCD in rural and        
underserved areas of Georgia. 
 
Sickle cell disease (SCD) is a genetic blood disorder caused          
by a defect in protein structure – an aberration in the red cell             
oxygen transport molecule, hemoglobin, (Pauling, et. al.,       
1941) wherein the amino acid glutamate is replaced by         
valine. This amino acid substitution causes a distortion in         
the shape of red blood cells from the normal biconcave disk           
shape, producing rigid, sticky, sickle-shaped cells. These       
sickle cells obstruct small blood vessels and capillaries        
disrupting the flow of oxygen to body tissues. The         
obstruction in the flow of blood coupled with oxygen         
deprivation to tissues cause severe and debilitating pain,        
known a vaso-occlusive episode (commonly referred to as        
sickle cell or pain crises). The episodes are part of a genetic            
pleiotropic effect that may impact every organ in the body,          
causing multiple medical complications (Ilesanmi, 2013).      
SCD is a complex, chronic illness affecting approximately        
100,000 Americans. In the United States (U.S.) the disorder         
is most prevalent among individuals of African descent,        
followed by individuals of Hispanic, Middle Eastern, and        
Indian descent. 
 
Despite being the first identified molecular disorder (in        
1910 and 1949), (Pauling, et. al., 1941) the progress in the           
  
  
care, management, and survival of people with SCD has         
lagged significantly. Advances in SCD treatment have been        
limited compared with later discovered molecular disorders,       
such as cystic fibrosis (CF)where more treatments have        
been developed to benefit patient populations. Though both        
are devastating conditions with shortened life expectancies,       
between 2009 and 2013, there were nearly twice as many          
publications and slightly more clinical trials for CF than         
SCD. Between 2010 and 2013, five new drugs were         
developed for CF and none were developed for SCD         
(Strouse, et. al., 2013). 
 
Before the 1970s, most children with SCD in the U.S. died           
before adolescence. Advances in treatment and the       
establishment of comprehensive, highly specialized     
pediatric centers decreased the mortality rate for children        
with SCD by 3 percent each year in a study from 1979 to             
2005 (Lanzkron, 2013). The collective scientific and       
medical focus was on preventing children from dying.        
However, there was little foresight regarding what happens        
to these children when they become adults. The Lanzkron         
(2013) study found that mortality rates for adults with SCD          
increased by 1 percent during the same period with a life           
expectancy reduced by approximately 30 years. Currently,       
the only available cure is limited to bone marrow         
transplantation and the promise of gene therapies currently        
in clinical trials. Options available to only a very small          
segment of the SCD population. Of the 762 drugs approved          
by the U.S. Food and Drug Administration for orphan         
diseases (population <200,000) between 1983 and 2018,       
only two were for SCD (U.S. Food, 2019 & U.S. Food,           
2019). Two additional drugs were introduced in 2019. 
 
Medical complications and frequent hospitalizations often      
disrupt the lives of individuals living with SCD, interrupting         
schooling and compromising their ability to maintain steady        
employment. This leaves some segments of adults with SCD         
uninsured and underinsured making most SCD centers       
money-losing cost centers. As a result, the number of         
hematologists, core providers for individuals with SCD,       
who care for patients with nonmalignant conditions is        
distressingly low (Marshall, 2018). The lack of health care         
providers with comprehensive knowledge to care for       
individuals with SCD makes it difficult for individuals to         
receive the standard of care necessary to improve health         
outcomes and reduce mortality. 
 
Georgia is the 9th most populous state in the U.S. (U.S.           
Census Bureau, 2020) with the fourth largest population of         
individuals with SCD (8,427) nation-wide (Hassel, 2010).       
Of the 159 counties in the state, 148 (93%) are designated as            
medically underserved and 108 counties (68%) are rural        
(population=<35,000) (Georgia State Office of Rural      
Health, 2011). The state has two comprehensive SCD        
centers for adults located in North (Metropolitan Atlanta)        
and East Central (Augusta) Georgia, with hematologists       
centralized in those areas. Non-specialty health care       
providers throughout the state reported reluctance to care for         
individuals with SCD because of lack of knowledge and         
negative perceptions of individuals with SCD; and would        
prefer to refer them to specialists (Georgia Health Policy         
Center, 2014). Consequently, individuals with sickle cell       
disease face a minimum two-hour drive for specialty care         
often creating a higher reliance on emergency departments        
at significantly higher costs and decreased quality of care. 
 
Engaging non-hematologists as care providers for      
individuals with SCD is vital to addressing the provider         
deficit. Training by skilled SCD providers could greatly        
enhance the knowledge and confidence of primary care        
providers, especially if training is coupled with access to a          
hematologist. Leveraging available capacity within existing      
medical center infrastructure can be an effective mechanism        
for creating care programs for individuals with SCD at a          
lower cost. Federally Qualified Health Centers (FQHC)       
could be a key support because of their focus on disease           
prevention and long-term management of chronic conditions       
(Access to Care Summit proceedings, 2019).  
 
Increasing access to care requires patient support.       
Individuals with SCD face several challenges, including       
navigating a maze of providers, scheduling appointments,       
and managing a large array of medication and medical         
regimes. Additionally, social determinants of health –       
inadequate housing, food insecurity, understanding of      
disease self-management, etc. can impact health seeking       
behaviors and undermine health outcomes. Community      
Health Workers (CHWs) are trusted, knowledgeable      
frontline health personnel who typically come from the        
communities they serve. CHWs bridge cultural and       
linguistic barriers, expand access to coverage and care, and         
improve health outcomes. As critical links between their        
communities and the health care system, CHWs reduce        
health disparities; boost health care quality, cultural       
competence and affordability; and empower individuals and       
communities for better health (American Public Health       
Association, 2009). In a study conducted by Overholser, et.         
al. (2014) utilizing CHWs to increase access to care by          
individuals with sickle cell disease, 62% of patients        
identified a primary care provider and attended a first         
appointment. CHWs help bridge to medical services to        
improve healthcare engagement, self-management,    
treatment plan adherence, and health outcomes (Hsu, 2016).        
Such patient assistance programs are associated with fewer        
missed appointments, which correlate with costly      




Phase I Community Health Workers  
SCFG secured Health Resources and Services      
Administration (HRSA) Sickle Cell Disease Newborn      
Screening funding in 2015 for two years (2015-2016)        
through the Sickle Cell Disease Association of America        
(SCDAA) to start a CHW Program to improve the health          
outcomes of individuals living with SCD. During the first         
  
  
year of funding (2015), SCFG developed a five-year plan         
presented to the Georgia State Legislature to increase access         
to care with incremental funding. The five-year plan        
proposed a public-private partnership between the state and        
community organizations to improve the quality of life and         
SCD care access in the state of Georgia. Registry and          
Surveillance System for Hemoglobinopathies (RuSH) data      
were used to target areas of the state with high rates of SCD             
and community potential partners were identified: 
● Augusta – East Georgia 
● Columbus – Midwest Georgia 
● Macon – Central Georgia 
● Savannah – Southeast Georgia 
 
During this first two-year period of the project, CHWs were          
located in Metropolitan Atlanta and in Columbus in        
partnership with the local sickle cell association. SCFG        
engaged the local community partner to generate strategies        
that would be implemented in the Columbus area to improve          
health outcomes of individuals living with SCD. The local         
partner identified the needs of individuals in Columbus        
living with SCD, their health seeking behaviors, and        
available community resources. Included in the planning       
process was the identification of potential candidates to        
serve as a CHW for the Columbus area. The local partner           
provided office space for the CHW and collaborated with         
the CHW to identify individuals with SCD in need of care           
coordination services.  
 
In 2017, SCFG expanded the deployment of CHWs to         
Augusta and Macon; and initiated planning for expansion to         
Savannah. SCFG partnered with the sickle cell support        
group in Macon to provide office space. In each of the           
cities, CHWs established partnerships with the local health        
departments, FQHCs, hospitals, clinics, and community      
organizations. Community partners served as a source of        
referrals for the CHW and a resource for primary care and           
other community services. CHWs provided appointment      
assistance, resource coordination, linkages to primary care,       
and follow-up. In Macon, the CHW partnered with the         
telemedicine hematology team to ensure individuals kept       
their appointments and were linked to a primary care         
provider. 
 
In 2018, a CHW was hired to service Savannah and the           
surrounding area. SCFG worked closely with the local SCD         
association to establish a relationship with one of the         
FQHCs in Savannah. The partnership with the FQHC        
included office space for the CHW and clinical space for a           
visiting hematologist. Through efforts of the CHW, the        
FQHC serves as a medical home for un-insured and         
under-insured individuals with SCD in Savannah. The CHW        
quickly established a partnership with the Memorial Health        
Children’s Hospital of Savannah and provides support to the         
hospital’s transition program, established in 2019.  
 
Phase II: Provider Training 
In 2018, SCFG initiated provider training in areas of the          
state with no hematologist. A curriculum was developed to         
include caring for persons with SCD in non-specialty        
settings; overview of SCD; pain management; emerging       
trends; protocols for management in emergency settings;       
and care coordination using CHWs. The 2014 National        
Heart, Lung, and Blood Institute’s “Evidence-Based      
Management of Sickle Cell Disease” (U.S. Department of        
Health and Human Services, 2014) is used as a basis for           
clinical instruction. The training is led by an expert         
hematologist and a family medicine physician with       
extensive experience with SCD treatment in family       
medicine and emergency department settings. In partnership       
with Morehouse School of Medicine, providers earn up to         
four CME credits for the four-hour course. Providers are         
encouraged to participate in the Extension for Community        
Health Care Outcomes (ECHO) sponsored by Atrium       
Health for additional training and to enroll in the U.S.          
Department of Health and Human Services, Office of        
Minority Health Sickle Cell Disease Training and       
Mentoring Program (STAMP) to gain access to       
consultations with sickle cell experts. 
 
A toolkit (see Appendix for list of contents) was developed          
and is disseminated during the training to include the         
American Society of Hematology clinical pocket guides of        
evidence-based practices, emergency department protocols,     
and other physician-focused materials. Training participants      
have included family medicine providers, nurse      
practitioners, pediatricians, internists, nurses, OB/GYN     
providers, emergency department physicians, physician     
assistants, medical assistants, and medical students. SCFG       
collaborated with local stakeholders to plan, coordinate, and        
deliver training – community based organizations, health       
departments, academic institutions, hospitals, FQHCs, and      
local SCD organizations. Local partners identify facilities,       
assist with marketing; and in some instances, participate as         
presenters. 
 
Phase III: Sickle Cell Clinic Days 
In 2019, SCFG established Memoranda of Understanding       
(MOU) and Business Associates Agreements with      
community health centers, health departments, and FQHCs       
in Columbus, Macon, and Augusta to host “Sickle Cell         
Disease Clinic Days” at their facilities. SCFG Medical        
Director and Operations Manager collaborated with the       
Clinical Directors to establish protocols to be used at each          
facility – appointment setting; facility enrollment (at       
FQHCs); lab work; facility liaison; medical record sharing;        
forms; intake; prescriptions; etc. 
 
The first clinic day was held at a FQHC in Savannah           
followed by clinic days at a FQHC and a community health           
center in Columbus. In Savannah, the CHW makes        
appointments and facilitates FQHC enrollment for labs,       
prescriptions, and primary care. The facility provides a        
nurse liaison to expedite any lab work needed. In Columbus,          
both facilities have patients with SCD and appointments are         
  
  
managed by facility staff. New patients are also managed by          
facility staff. The hematologist makes monthly visits to the         




Since inception, 869 individuals in 75 Georgia counties        
have received care coordination services with 113 placed in         
medical homes (primary care). The Social Functioning and        
Emotional Distress Scales of the Adult Sickle Cell Quality         
of Life Measurement System (ASCQ-Me short forms) were        
used to measure changes in the two constructs of individuals          
receiving CHW services in Metropolitan Atlanta, July       
through December 2019. Seventy-two percent (72.4%) of       
individuals receiving services reported improvement in      
social functioning (less difficult to engage in social        
functions, less difficult to get out and do things they enjoy).           
Respondents reported that after receiving CHW services,       
they: 
● relied less on others to take care of them 
● were slowed down less by their health  
● found it less difficult for them to do the things they           
like 
● were prevented from going out less often 
● found it less difficult to do things with their friends 
Sixty-eight percent (68.7%) reported improvement in      
emotional distress (worried less about getting sick and        
needing to go to the hospital). Respondents reported that         
after services, they experienced: 
● reduced feelings of complete hopelessness because      
of their health 
● reduced feeling of loneliness  
● less depressed feelings about their health problems 
● less worry about getting sick 
● less worry about needing to go to the hospital 
 
Three hundred and sixty-eight health care providers have        
participated in six face-to-face trainings and 30 have        
participated in two webinars.  
● 91% reported increases in disease knowledge 
● 87% reported increases in knowledge of disease       
management and treatment, and better     
understanding of patient experience 
● 77% reported improved comfort levels treating      
individuals with SCD 
● 89% reported a desire for a follow-up support        
mechanism 
 
A total of 40 patients have been seen at the FQHCs and            
community health center in Savannah and Columbus.       
Patients have reported high levels of satisfaction with the         
services received and the number of patients is slowly         
increasing. A small number of patients from the southern         
part of the state travel an hour or more to their Sickle Cell             
Clinic Day appointment in Savannah. However, most       
identify not having to drive long distances to see a          
hematologist as the most significant advantage of the Sickle         




This project builds on leveraging existing resources, thus        
taking the time to understand the local landscape is critical          
to the successful implementation of this kind of project.         
Local stakeholder input and ownership requires time and        
patience. Each location has its own politics, culture, and         
motivations for project involvement and each presents       
lessons learned to be applied to the next location. For          
example, the patient profile in Columbus differs greatly        
from the patient profile in Savannah. Columbus has no         
hematologists, adult or pediatric. Over the last year, a         
monthly pediatric SCD clinic has operated out of a local          
pediatrician’s office. Adult patients in Columbus are diverse        
in age, income, and educational levels and have had to drive           
two hours to see a hematologist. In many instances, they          
have been in care though not as regularly because of the           
need to travel. Savannah has a very limited number of          
hematologists. Most of the Savannah Sickle Cell Clinic        
Days patients tend to be young adults – college students or           
recent graduates with limited income and no insurance.        
Many of the Savannah patients had not seen a hematologist          
in over a year and had been receiving care in emergency           
departments and urgent care centers. Some are emerging        
adults making their first adult appointment before leaving        
pediatric care. A small number are established adults from         
the more southern part of the state with no hematologists.  
 
In Columbus we discovered variability in capacity and        
infrastructure of community health centers that we had not         
expected. During a clinic day, we found that one of the           
centers did not have a laboratory on site and used a third            
party. The lesson learned is to collect comprehensive        
capacity information from potential partners to determine       
the most efficient and practical way to provide hematology         
services in that location. It is also necessary to ascertain if           
the location is suitable for a one-day clinic. 
 
The CHW program has served as the foundation for the          
overall project. Not only do they serve as liaisons between          
the individuals living with SCD and medical and        
community resources, because they are an established part        
of the community, they serve as liaisons between local         
stakeholders and other aspects of the project. They also play          
an important role in getting individuals to their        
appointments with both reminders and support, such as        
arranging transportation. Within the FQHCs and community       
health centers, relationships have been forged between the        
visiting hematologist and the SCFG Medical Director       
(family practice). Increasingly, FQHC providers are      
reaching out to the SCFG clinical staff for consultations on          
specific cases involving individuals with SCD they are        
caring for. 
 
SCFG is a non-clinical community based organization and        
there was a learning curve in understanding how to actually          
provide clinical services in these very different communities        
  
  
and how the CHWs function. We grossly overestimated the         
number of patients that the hematologist could see in a visit,           
underestimated the amount of time needed for new patients,         
and did not account for the time needed for both          
stakeholders and patients to get acclimated to the program.         
Because significant travel is involved for the hematologist,        
establishing predictable, monthly schedules for the cities       
saves on travel costs. A consideration to expand the reach of           
adult hematology services is to ramp up the utilization of          
telemedicine. This presents an additional learning curve for        
implementation and interface with our community partners.       
Investigating strategies and infrastructure requirements to      
offer virtual training and real time consultation to        
non-specialty providers can expand the number of providers        
that can be trained and ultimately grow the pool of providers           
who can deliver knowledgeable and appropriate care for        
SCD across the state. 
 
IMPLICATIONS FOR PUBLIC HEALTH 
 
This project is an example of finding ways to utilize existing           
resources in areas that are poorly resourced, looking beyond         
the deficits in underserved and under-resourced areas and        
finding ways to leverage and build on the resources that are           
in place. The SCFG Access to Care Project takes an          
innovative approach working with a diverse group of        
stakeholders to plan, implement, and evaluate the project.        
SCFG engaged with community organizations during both       
the planning and implementation stages of the project.        
Community stakeholder meetings included representatives     
of community organizations, health care providers, and       
individuals living with sickle cell disease. Stakeholders       
identified community needs, strengths, and resources and       
identified potential community partners. State and local       
level policy makers provided input on the areas of the state           
in need of services; developed state policies; and made         
resources available to implement project activities. The       
project collaborated with public, private, and faith-based       
community health centers to develop protocols and       
processes needed to provide hematology care to individuals        
with SCD in their areas and to increase access to primary           
and other sub-specialty care (behavioral health, OB/GYN).       
Physicians and consultants in private practice plan the        
delivery of medical services and collaborate with academic        
institutions to plan and deliver training for health care         
providers. 
 
This project engaged partners across disciplines (including       
individuals living with SCD); encouraged and granted local        
ownership of project activities; and demonstrated flexibility       
in mid-course operations corrections. This strategy resulted       
in increased access to care in underserved areas of the state           
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Provider Training Toolkit Contents 
 
Information 
● Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease: A Pocket Guide for the Clinician, 2014, 
American Society of Hematology, ​www.hematology.org  
● Management of Complications of Sickle Cell Disease: A Pocket Guide for the Clinician, 2014, American Society of 
Hematology, ​www.hematology.org  
● Health Maintenance and Management of Chronic Complications of Sickle Cell Disease: A Pocket Guide for the 
Clinician, 2014, American Society of Hematology, ​www.hematology.org  
● Red Blood Cell Transfusion: A Pocket Guide for the Clinician, 2016, American Society of Hematology, 
www.hematology.org 
● Emergency Management of Sickle Cell Disease, National Heart, Lung and Blood Institute algorithm for the management 
of acute pain crises 
● Hydroxyurea (patient brochure), Sickle Cell Disease Association of America/Sickle Cell Foundation of Georgia 
● Living Well with Sickle Cell: Community Health Services for People with Sickle Cell, Georgia Community 
Connections, Sickle Cell Foundation of Georgia  
● Sickle Cell Disease and Family Planning, Sickle Cell Foundation of Georgia 
 
Additional Training Opportunities 
● Fact Sheet and Enrollment Information – The Sickle Cell Disease (SCD) Training and Mentoring Program (STAMP): A 
Pilot Program for Primary Care Providers, U.S. Department of Health and Human Services, Office of Minority Health 
● Fact Sheet and Schedule – Improve Sickle Cell Care and Outcomes with Project ECHO, Atrium Health, Levine Cancer 
Institute 
● Training Description and Access Information – Reducing Complications of Therapeutic Blood Transfusion for Sickle 
Cell Disease, Georgia Health Policy Center, Georgia State University 
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